Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

Impact · against what's priced in

The announcement of a lead plaintiff deadline for the class action against Immutep reinforces the company's severe devaluation following the TACTI-004 trial failure. For GPK and CHX, the news introduces new legal risks as Robbins LLP seeks lead plaintiffs for separate, unspecified litigations.

CHX−0.30: No priced-in read yet

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

What matters in this story

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

What matters in this story

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

How each ticker is affected

Track these names every morning.

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Millrose Properties, Inc. of Class Action Lawsuit and Upcoming Deadlines – MRP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming Deadlines – DOCS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

What matters in this story

Next reads from the same story arc

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

What matters in this story

Next reads from the same story arc

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

How each ticker is affected

Track these names every morning.

Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Millrose Properties, Inc. of Class Action Lawsuit and Upcoming Deadlines – MRP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming Deadlines – DOCS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT